Viral load monitoring of antiretroviral therapy, cohort viral load and HIV transmission in Southern Africa: a mathematical modelling analysis

Objectives:In low-income settings, treatment failure is often identified using CD4 cell count monitoring. Consequently, patients remain on a failing regimen, resulting in a higher risk of transmission. We investigated the benefit of routine viral load monitoring for reducing HIV transmission. Design:Mathematical model. Methods:We developed a stochastic mathematical model representing the course of individual viral load, immunological response and survival in a cohort of 1000 HIV-infected patients receiving antiretroviral therapy (ART) in southern Africa. We calculated cohort viral load (CVL; sum of individual viral loads) and used a mathematical relationship between individual viral load values and transmission probability to estimate the number of new HIV infections. Our model was parameterized with data from the International epidemiologic Databases to Evaluate AIDS Southern African collaboration. Sensitivity analyses were performed to assess the validity of the results in a universal ‘test and treat’ scenario, wherein patients start ART earlier after HIV infection. Results:If CD4 cell count alone was regularly monitored, the CVL was 2.6 × 106 copies/ml and the treated patients transmitted on average 6.3 infections each year. With routine viral load monitoring, both CVL and transmissions were reduced by 31% to 1.7 × 106 copies/ml and 4.3 transmissions, respectively. The relative reduction of 31% between monitoring strategies remained similar for different scenarios. Conclusion:Although routine viral load monitoring enhances the preventive effect of ART, the provision of ART to everyone in need should remain the highest priority.

[1]  James M Robins,et al.  When to Initiate Combined Antiretroviral Therapy to Reduce Mortality and AIDS-Defining Illness in HIV-Infected Persons in Developed Countries , 2011, Annals of Internal Medicine.

[2]  D. Havlir,et al.  "A bird in the hand...": a commentary on the test and treat approach for HIV. , 2010, Archives of internal medicine.

[3]  M. Zwahlen,et al.  Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies , 2008, Sexually Transmitted Infections.

[4]  M. Egger,et al.  Public-Health and Individual Approaches to Antiretroviral Therapy: Township South Africa and Switzerland Compared , 2008, PLoS medicine.

[5]  HOMAS,et al.  VIRAL LOAD AND HETEROSEXUAL TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 VIRAL LOAD AND HETEROSEXUAL TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 , 2000 .

[6]  Summary TOWARDS UNIVERSAL ACCESS : Scaling up Priority HIV / AIDS Interventions in the Health Sector Progress Report , 2008 .

[7]  E. Vittinghoff,et al.  Decreases in Community Viral Load Are Accompanied by Reductions in New HIV Infections in San Francisco , 2010, PloS one.

[8]  Matthew G Law,et al.  Relation between HIV viral load and infectiousness: a model-based analysis , 2008, The Lancet.

[9]  William C Miller,et al.  The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study , 2011, The Lancet.

[10]  Kara Wools-Kaloustian,et al.  Cohort Profile: the international epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa. , 2012, International journal of epidemiology.

[11]  R Weber,et al.  HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. , 2001, JAMA.

[12]  M. Egger,et al.  Correcting Mortality for Loss to Follow-Up: A Nomogram Applied to Antiretroviral Treatment Programmes in Sub-Saharan Africa , 2011, PLoS medicine.

[13]  N. Ford,et al.  Life Expectancy of Persons Receiving Combination Antiretroviral Therapy in Low-Income Countries: A Cohort Analysis From Uganda , 2011, Annals of Internal Medicine.

[14]  T. Hallett,et al.  Examining the promise of HIV elimination by ‘test and treat’ in hyperendemic settings , 2010, AIDS.

[15]  Organización Mundial de la Salud,et al.  Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report 2009 , 2009 .

[16]  G. Rutherford,et al.  Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. , 2013, The Cochrane database of systematic reviews.

[17]  A. Wensing,et al.  Evolutionary pathways of transmitted drug-resistant HIV-1. , 2011, The Journal of antimicrobial chemotherapy.

[18]  Christopher Dye,et al.  Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model , 2009, The Lancet.

[19]  B. Stilwell,et al.  Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. , 2006 .

[20]  G. Rutherford,et al.  Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda , 2006, AIDS.

[21]  P. Mee,et al.  Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa , 2008, AIDS.

[22]  Michael Rayment,et al.  Prevention of HIV-1 infection with early antiretroviral therapy , 2012, Journal of Family Planning and Reproductive Health Care.

[23]  R. Wood,et al.  Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/μl is associated with improved treatment outcomes in South Africa , 2010, AIDS.

[24]  Matthias Egger,et al.  Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis , 2009, AIDS.

[25]  Michael J Silverberg,et al.  Effect of early versus deferred antiretroviral therapy for HIV on survival. , 2009, The New England journal of medicine.

[26]  U. Unicef,et al.  Global HIV/AIDS response: epidemic update and health sector progress towards universal access: progress report 2011. , 2011 .

[27]  Stephen R Cole,et al.  Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies , 2009, The Lancet.

[28]  V. Mishra,et al.  HIV transmission risk behavior among HIV-infected adults in Uganda: results of a nationally representative survey , 2008, AIDS.

[29]  B. Haynes,et al.  Acute HIV-1 Infection. , 2011, The New England journal of medicine.

[30]  B. Thiers,et al.  Relation between HIV viral load and infectiousness: a model-based analysis , 2009 .

[31]  T. Hallett,et al.  The Impact of Monitoring HIV Patients Prior to Treatment in Resource-Poor Settings: Insights from Mathematical Modelling , 2008, PLoS medicine.

[32]  Myron S. Cohen,et al.  Honing the test-and-treat HIV strategy. , 2010, Science.

[33]  Stephen T. Wright,et al.  CD4 Cell Responses to Combination Antiretroviral Therapy in Patients Starting Therapy at High CD4 Cell Counts , 2011, Journal of acquired immune deficiency syndromes.

[34]  M. Egger,et al.  Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy , 2009, Tropical medicine & international health : TM & IH.

[35]  Nicolas Bacaër,et al.  An Age-Structured Model for the Potential Impact of Generalized Access to Antiretrovirals on the South African HIV Epidemic , 2010, Bulletin of mathematical biology.

[36]  R. Chaisson,et al.  Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions , 1999, Annals of Internal Medicine.

[37]  Mark J van der Laan,et al.  Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification , 2008, AIDS.

[38]  A. Dick A bird in the hand . . . , 2002, British Journal of Ophthalmology.

[39]  B. Chi,et al.  Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in southern Africa , 2011, AIDS.

[40]  A. Wensing,et al.  Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. , 2010, The Lancet. Infectious diseases.

[41]  Milton C Weinstein,et al.  The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States , 2006, Medical care.